 to fast track clinical trials of the indigenous COVID 19 vaccine (BBV152 COVID Vaccine).){kind=link}
The Indian Council of Medical Research has informed that it has partnered with Bharat Biotech International Limited (BBIL) to fast track clinical trials of the indigenous COVID 19 vaccine (BBV152 COVID Vaccine).
The vaccine named “Covaxin” according to ICMR is the first indigenous vaccine being developed by India and is one of the top priority projects which is being monitored at the topmost level of the Government. The Vaccine is derived from a strain of SARS-CoV-2 isolated by ICMR National Institute of Virology, Pune. Bothe ICMR and BBIL are working together for the preclinical as well as clinical development of the vaccine.
The vaccine is stated to be launched for public health use latest by August 15, 2020 after completing all clinical trials.
BBIL is working expeditiously to meet the targets, however final outcome will depend on the cooperation of all clinical trial sites involved in the project.
The institutes that have been selected for the clinical trial are in Visakhapatnam, Rohtak, New Delhi, Patna, Belgaum (Karnataka), Nagpur, Gorakhpur, Kattankulathur (Tamil Nadu), Hyderabad, Arya Nagar, Kanpur (Uttar Pradesh) and Goa.
While the COVID 19 cases are surging day after day and Scientists around the world are giving in their best efforts to develop a vaccine for COVID 19 cure, no vaccine has been successfully developed so far.
-India Legal Bureau